Trial reportScientific reports2022
Reliability and validity of the Roche PD Mobile Application for remote monitoring of early Parkinson's disease.
Trial report in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 57 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase II Study to Evaluate the Efficacy of Intravenous RO7046015/Prasinezumab (PRX002) in Participants With Early Parkinson's Disease With a 11-Year All-Participants-on-Treatment Extension
Slow-SPEED-United Kingdom: A Double-Blind Randomised Feasibility Trial of a Remote Gamified Physical Activity Programme in Adults With Hyposmia.
Who cites it
57 citing papers in PubMed, 3 syntheses or guidelines pooled it, 104 citations in OpenAlex.
- Real-world gait study of Parkinson's disease using wearable sensors: a systematic review.Journal of neuroengineering and rehabilitation · 2026Pooled it
- Wearable Devices for Remote Monitoring of Chronic Diseases: Systematic Review.JMIR mHealth and uHealth · 2026Pooled it
- Movement Disorders and Smart Wrist Devices: A Comprehensive Study.Sensors (Basel, Switzerland) · 2025Pooled it
- Telemedical communication patterns in myasthenia gravis in a remote monitoring study.Neurological research and practice · 2026Article
- Bridging the global Parkinson's divide: Technology as a structural solution for equitable and brain health-integrated care.Journal of Parkinson's disease · 2026Review
- From past to future: Digital approaches to success of clinical drug trials for Parkinson's disease.Journal of Parkinson's disease · 2026Review
- National implementation of a digital Parkinson's disease screening programme in Thailand: reach, adoption, and real-world performance of the CheckPD app.BMC public health · 2026Article
- Scalable biomarkers of Parkinson's disease: insights from mobile EEG in Peru.Scientific reports · 2026Article
- Multimodal Intelligent Monitoring of Parkinson Disease: Scoping Review of Progress and Translational Challenges.Journal of medical Internet research · 2026Article
- Speech Biomarkers From Smartphone Calls Track Progression in REM Sleep Behavior Disorder and Parkinson's Disease.Annals of neurology · 2026Article
- Digital Technologies for Symptom Monitoring in Parkinson Disease.Current neurology and neuroscience reports · 2026Review
- Clinical translation of fluid, imaging, and digital biomarkers for Alzheimer's disease.Alzheimer's research & therapy · 2026Review
- Identifying and predicting fast versus slow Parkinson's disease motor progressors using clinical and digital data.BMJ neurology open · 2026Article
- Improving Prediction of Falls and Cognitive Impairment in Parkinson Disease: Protocol for a Decentralized Observational Study.JMIR research protocols · 2025Article
- Immunization targeting diseased proteins in synucleinopathy and tauopathy: insights from clinical trials.Translational neurodegeneration · 2025Review
- Digital speech biomarkers can measure acute effects of levodopa in Parkinson's disease.NPJ Parkinson's disease · 2025Article
- Wrist accelerometry and machine learning sensitively capture disease progression in prodromal Parkinson's disease.NPJ Parkinson's disease · 2025Article
- Exploratory digital outcome measures of motor sign progression in Parkinson's disease patients treated with prasinezumab.NPJ digital medicine · 2025Article
- Digital Health in Parkinson's Disease and Atypical Parkinsonism-New Frontiers in Motor Function and Physical Activity Assessment: Review.Journal of clinical medicine · 2025Review
- Digital health technology for Parkinson's disease with comprehensive monitoring and artificial intelligence-enabled haptic biofeedback for bulbar dysfunction.Journal of Parkinson's disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Digital health technologies enable remote and therefore frequent measurement of motor signs, potentially providing reliable and valid estimates of motor sign severity and progression in Parkinson's disease (PD). The Roche PD Mobile Application v2 was developed to measure bradykinesia, bradyphrenia and speech, tremor, gait and balance. It comprises 10 smartphone active tests (with ½ tests administered daily), as well as daily passive monitoring via a smartphone and smartwatch. It was studied in 316 early-stage PD participants who performed daily active tests at home then carried a smartphone and wore a smartwatch throughout the day for passive monitoring (study NCT03100149). Here, we report baseline data. Adherence was excellent (96.29%). All pre-specified sensor features exhibited good-to-excellent test-retest reliability (median intraclass correlation coefficient = 0.9), and correlated with corresponding Movement Disorder Society-Unified Parkinson's Disease Rating Scale items (rho: 0.12-0.71). These findings demonstrate the preliminary reliability and validity of remote at-home quantification of motor sign severity with the Roche PD Mobile Application v2 in individuals with early PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.